Skip to main content

Table 4 Comparison of 2-year outcomes between MAC and RIC haplo-SCT according to disease status

From: Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT

Disease Patients group and p value RI NRM LFS OS cGVHD
Diagnosis AML 36.1 % (31.6–40.6) 31.6 % (27.4–35.9) 32.2 % (27.7–36.7) 37.7 % (33.1–42.4) 29.2 % (24.8–33.7)
  ALL 40 % (32.5–47.3) 32.9 % (28.6–37.2) 27.2 % (20.2–34.1) 33.3 % (25.9–40.7) 29.8 % (22.8–37.2)
  p 0.43 0.87 0.45 0.40 0.67
All patients       
 CR1 RIC 30.1 % (19.1–41.9) 31.1 % (24.1–38.3) 38.9 % (26.4–51.3) 46.9 % (34.1–59.8) 26 % (15–38.3)
  MAC 21.5 % (15.4–28.3) 29.1 % (22.2–36.3) 49.1 % (41.2–57.1) 55.4 % (47.5–63.4) 41 % (32.8–48.9)
  p 0.21 0.80 0.42 0.64 0.10
  ≥ CR2 RIC 38.5 % (25.8–51.1) 36.8 % (28.2–45.5) 24.6 % (13.1–36.1) 29.8 % (17.7–41.9) 29.6 % (17.5–42.8)
  MAC 30 % (21.5–39) 27.8 % (19.7–36.4) 42.2 % (32.6–51.7) 47.7 % (38–57.5) 37 % (27.4–46.6)
  p 0.38 0.25 0.06 0.07 0.53
 Active dis. RIC 55.8 % (45.9–64.6) 32.9 % (24.5–41.5) 11.3 % (5–17.5) 14.3 % (7.3–21.3) 21.4 % (13.8–30.1)
  MAC 51.9 % (42.3–60.6) 37.1 % (28.6–45.7) 11 % (4.7–17.2) 18.5 % (11.2–25.7) 15.2 % (9.2–22.7)
  P 0.52 0.38 0.64 0.60 0.29
  1. Active dis active disease, cGVHD chronic graft-versus-host disease, CR complete remission, LFS leukemia-free survival, NRM non-relapse mortality, MAC myeloablative conditioning, OS overall survival, RI relapse incidence, RIC reduced intensity conditioning